Back to results
US 5,705,477 AGranted
Compositions of transforming growth factor .beta.(TGF-.beta.) which promotes wound healing and methods for their use
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsMichael B. Sporn, Anita B. Roberts
Life of this patent
Estimating the term…
Abstract
A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.
Claims27
A pharmaceutical composition, comprising:
- beta-transforming growth factor (TGF-.beta.) having the following characteristics;
- (a) does not compete with epidermal growth factor (EGF) for receptor binding;
- (b) induces dose dependent formation of large colonies having a size of greater than 3,100 .mu.m.sup.2 of NRK 49F cells in a soft agar assay when activated by EGF or transforming growth factor-alpha (TGF-.alpha.) and
- (c) if not activated by EGF or transforming growth factor-alpha, does not induce NRK cells to form said large colonies in soft agar;
- and
- a pharmaceutically acceptable carrier therefor.
3 more elements
A pharmaceutical composition, comprising:
- isolated and substantially homogeneous beta transforming growth factor (TGF-.beta.) having the following characteristics:
- (a) acid stable;
- (b) an apparent molecular weight of about 25,000 to 26,000 daltons in the absence of a reducing agent as measured by SDS-PAGE;
- (c) an apparent molecular weight of about 12,500 daltons under reducing conditions as measured by SDS-PAGE;
- (d) does not compete with epidermal growth factor for receptor binding;
- (e) induces dose-dependent formation of large colonies having a size of greater than >3,100 .mu.m.sup.2 of NRK 49F cells in a soft agar assay when activated by epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-.alpha.);
- being purified to the extent that
- (1) it does not induce NRK cells to form said large colonies in soft agar and
- (2) it produces a single band with an apparent molecular weight of about 12,500 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 25,000 is shown under non-reducing conditions;
- and
- a pharmaceutically acceptable carrier therefor.
8 more elements
Dependencies are inferred from the claim text.